Business context and reporting period
Entity discrepancy: Request metadata names Vivosim Labs, Inc., but the supplied Form 10-Q is for Organovo Holdings, Inc. The summary below covers the filing provided, not Vivosim Labs.
Organovo is an early-commercial-stage biotechnology company developing 3D-bioprinted human tissues for drug research and potential therapeutic use. This is its fiscal third quarter, for the three months ended December 31, 2016, and its nine-month year-to-date period. The interim financial statements are unaudited.
Financial performance and condition
| Metric | Three months ended Dec. 31, 2016 | Nine months ended Dec. 31, 2016 |
|---|---|---|
| Revenue | $1.151 million | $3.418 million |
| Cost of revenue | $0.212 million | $0.773 million |
| Operating loss | $9.631 million | $27.887 million |
| Net loss | $9.581 million | $27.790 million |
| Net loss per share, basic and diluted | $0.09 | $0.29 |
| Operating cash used | Not presented for the quarter | $21.959 million |
Revenue less cost of revenue implies gross profit of approximately $0.939 million for the quarter and $2.645 million year to date. The filing does not present these as gross-margin metrics; prior-year cost of revenue was immaterial and included in research and development, limiting direct margin comparison.
At December 31, 2016, cash and cash equivalents were $69.996 million; working capital was $67.502 million (current assets $71.943 million less current liabilities $4.441 million). Total liabilities were $5.227 million, including deferred rent; the filing reports no borrowing debt. Accumulated deficit was $188.660 million. Cash rose $7.905 million from March 31, 2016, supported by $30.983 million of financing cash inflows, including a public offering and at-the-market stock sales.
Material changes versus prior comparable periods
- Quarterly revenue rose approximately 251% from $0.328 million; nine-month revenue increased approximately 266% from $0.935 million. Product and service revenue, mainly liver-tissue research services, and collaboration revenue drove the growth. Grant revenue declined year to date following completion of a significant prior-year grant.
- Quarterly net loss narrowed to $9.581 million from $10.455 million; nine-month net loss narrowed to $27.790 million from $30.203 million.
- Quarterly R&D increased 10% to $5.024 million, while nine-month R&D increased 4% to $14.012 million, reflecting staffing and development activity.
- Quarterly SG&A decreased 11% to $5.546 million and nine-month SG&A decreased 7% to $16.520 million, largely due to lower stock-based compensation and absence of prior-year executive-related costs; higher staffing partly offset the decreases.
- Operating cash use was broadly similar year over year: $21.959 million versus $21.836 million for the nine-month periods.
Outlook, risks, and notable items
- Management said available cash and its current operating plan were sufficient to fund operations for at least the next 12 months. Future capital needs depend on commercialization revenue and development spending; additional financing may be needed, may not be available on favorable terms, and equity financing would dilute shareholders.
- The company began commercial contracting for ExVive Human Kidney Tissue in September 2016 and reported commercial orders and customer studies. It also announced a preclinical development program for bioprinted liver tissue for possible transplantation, based on early animal-study results; this remains a development effort, not an established product or forecast.
- On October 25, 2016, the company sold 10.065 million shares in a public offering at $2.75 per share, receiving approximately $25.7 million net. It also raised approximately $4.5 million net through at-the-market sales during the nine-month period. Shares outstanding increased to 104.096 million at period end; potential equity awards, warrants, and plan reserves add dilution exposure.
- Key risks include ongoing losses and operating cash burn, uncertain commercial adoption and product development, dependence on future financing, and customer/collaborator concentration. The filing says there were no material changes to previously disclosed risk factors.
- The company disclosed $6.119 million of future minimum operating lease payments. It recorded no loss-contingency accrual and did not identify a probable or reasonably possible, estimable loss from legal matters. Management reported disclosure controls were effective and no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Organovo Holdings, Inc., despite the Vivosim Labs metadata.
- Track whether liver and kidney research services generate sustained revenue growth and whether collaboration revenue depends on milestones or a limited number of customers.
- Compare cash burn and cash runway in subsequent filings with management’s stated minimum 12-month funding outlook.
- Assess the effect of continued equity issuance, outstanding equity awards, warrants, and reserved shares on dilution.
- Monitor progress, costs, and evidence supporting the liver-tissue therapeutic program; the filing provides no commercialization guidance or quantified revenue outlook.